Galera Therapeutics, Inc.
OBX-115
NSCLC
Countdown
358days
Phase 1 readout Β· ~ Jun 30, 2027 estimated
What's at stake
Phase 1 trial results for OBX-115 in NSCLC are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
Β· SEC 8-K
verified 15h ago
βNSCLC Phase 1 data 1H 2027β